The document provides continuing education information for various healthcare professionals on a presentation about managing respiratory symptoms in terminally ill patients, including cough, hemoptysis, and the "death rattle." It lists the organizations that provide continuing education credits for professionals who complete the program in different states and professions. Exceptions to credit approval are noted for certain states that do not provide credits for nursing home administrators.
Define and understand the types of advanced lung disease (ALD)
Discuss the impact of ALD on patients, family, and the health system
Describe the symptom burden of ALD
Appreciate factors associated with a poorer prognosis in ALD
Identify guidelines for referral to Hospice
Review the medical management of ALD
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of HospiceVITAS Healthcare
The goal of this webinar is to educate healthcare clinicians about the history, incidence, impact and identification of sepsis in the acute-care setting. Hospice care is inadequately utilized for patients with sepsis, a serious condition that results in 250,000 US deaths each year and an annual $3.5 billion in hospital readmission costs.
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
Chronic Obstructive Pulmonary Disease (COPD) is the third-leading cause of death in America, yet less than 9 percent of those patients near the end of life are admitted to hospice. These slides looks at the effects of COPD and other Advanced Lung Diseases (ALD) and how palliative care and hospice can improve patient care and clinical outcomes.
NOTICE:
This Webinar was intended to provide general educational information only. The information presented should not be viewed as specific medical advice regarding a particular patient. It is always a medical provider’s responsibility to individually assess and evaluate each patient before providing that patient medical advice or initiating any medical intervention.
A case study of a 66-year-old patient provides the backdrop for two potential clinical scenarios—sepsis and post-sepsis syndrome—and explores the natural history and indicators of poor prognosis in both conditions.
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD), the value of advance care planning (ACP), and the benefits of hospice for end-of-life patients.
A Change in Behavior: A Pragmatic Clinical Guide to Delirium, Terminal Restle...VITAS Healthcare
The goal of this webinar was to help physicians and healthcare professionals differentiate delirium, terminal restlessness, and dementia-related agitation and aggression in patients near the end of life.
Define and understand the types of advanced lung disease (ALD)
Discuss the impact of ALD on patients, family, and the health system
Describe the symptom burden of ALD
Appreciate factors associated with a poorer prognosis in ALD
Identify guidelines for referral to Hospice
Review the medical management of ALD
Sepsis & Hospice Eligibility: Natural History, Prognosis & Role of HospiceVITAS Healthcare
The goal of this webinar is to educate healthcare clinicians about the history, incidence, impact and identification of sepsis in the acute-care setting. Hospice care is inadequately utilized for patients with sepsis, a serious condition that results in 250,000 US deaths each year and an annual $3.5 billion in hospital readmission costs.
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
Chronic Obstructive Pulmonary Disease (COPD) is the third-leading cause of death in America, yet less than 9 percent of those patients near the end of life are admitted to hospice. These slides looks at the effects of COPD and other Advanced Lung Diseases (ALD) and how palliative care and hospice can improve patient care and clinical outcomes.
NOTICE:
This Webinar was intended to provide general educational information only. The information presented should not be viewed as specific medical advice regarding a particular patient. It is always a medical provider’s responsibility to individually assess and evaluate each patient before providing that patient medical advice or initiating any medical intervention.
A case study of a 66-year-old patient provides the backdrop for two potential clinical scenarios—sepsis and post-sepsis syndrome—and explores the natural history and indicators of poor prognosis in both conditions.
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD), the value of advance care planning (ACP), and the benefits of hospice for end-of-life patients.
A Change in Behavior: A Pragmatic Clinical Guide to Delirium, Terminal Restle...VITAS Healthcare
The goal of this webinar was to help physicians and healthcare professionals differentiate delirium, terminal restlessness, and dementia-related agitation and aggression in patients near the end of life.
The goal of this webinar is to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD) and the value of advance care planning for end-of-life patients.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
Success Principle 12: End of life care for COPDNHS Improvement
A series of mix and match cards providing practical examples of changes you can make and how to implement them to improve care and quality at every step of the pathway for patients with COPD and asthma.
The goal of this webinar was to educate healthcare professionals about the differences between palliative and curative care while exploring the history and philosophy of the hospice movement.
The goal of this webinar was to educate healthcare professionals about the differences between palliative and curative care while exploring the history and philosophy of the hospice movement.
The goal of this webinar was to help hospice and healthcare professionals understand the history, philosophy, and practice of hospice and palliative care.
This presentation describes the heart and its normal functions; describes the various disease processes of the heart; discusses cardiac disorders in terms of 4 categories; identify criteria used to determine if the cardiac patient is hospice appropriate.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
The goal of this webinar was to help hospice and healthcare professionals understand the history, philosophy, and practice of hospice and palliative care.
This webinar provides expert guidance and clear answers to common myths about hospice care. Learn about the history and philosophy of hospice care, common hospice prognoses, who pays for hospice, and the difference between hospice and palliative care. Explore the four levels of care and the role of the interdisciplinary hospice team to provide medical, psychosocial and spiritual solutions that support quality of life at the end of life for patients and families. Learn how advance directives can ensure patients are referred to hospice care early in the disease process to enjoy its full benefits.
The who, what, where, why and how of end-of-life care. A continuing education webinar presented by VITAS Healthcare on March 15, 2018. For more information or future webinars, please visit: https://www.vitas.com/partners/continuing-education
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and the benefits of hospice for patients with advanced cardiac disease (ACD).
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and benefits for patients with advanced cardiac disease (ACD).
The goal of this webinar is to help healthcare professionals improve care coordination for patients with advanced illness and to reduce hospital readmissions and length of stay (LOS).
The goal of this webinar is to educate healthcare professionals about the differences between palliative and curative care while exploring the history and philosophy of the hospice movement.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar is to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis and the “death rattle” in patients with end-of-life respiratory symptoms.
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD) and the value of advance care planning (ACP) for end-of-life patients.
The goal of this webinar is to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD) and the value of advance care planning for end-of-life patients.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
Success Principle 12: End of life care for COPDNHS Improvement
A series of mix and match cards providing practical examples of changes you can make and how to implement them to improve care and quality at every step of the pathway for patients with COPD and asthma.
The goal of this webinar was to educate healthcare professionals about the differences between palliative and curative care while exploring the history and philosophy of the hospice movement.
The goal of this webinar was to educate healthcare professionals about the differences between palliative and curative care while exploring the history and philosophy of the hospice movement.
The goal of this webinar was to help hospice and healthcare professionals understand the history, philosophy, and practice of hospice and palliative care.
This presentation describes the heart and its normal functions; describes the various disease processes of the heart; discusses cardiac disorders in terms of 4 categories; identify criteria used to determine if the cardiac patient is hospice appropriate.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
The goal of this webinar was to help hospice and healthcare professionals understand the history, philosophy, and practice of hospice and palliative care.
This webinar provides expert guidance and clear answers to common myths about hospice care. Learn about the history and philosophy of hospice care, common hospice prognoses, who pays for hospice, and the difference between hospice and palliative care. Explore the four levels of care and the role of the interdisciplinary hospice team to provide medical, psychosocial and spiritual solutions that support quality of life at the end of life for patients and families. Learn how advance directives can ensure patients are referred to hospice care early in the disease process to enjoy its full benefits.
The who, what, where, why and how of end-of-life care. A continuing education webinar presented by VITAS Healthcare on March 15, 2018. For more information or future webinars, please visit: https://www.vitas.com/partners/continuing-education
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and the benefits of hospice for patients with advanced cardiac disease (ACD).
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and benefits for patients with advanced cardiac disease (ACD).
The goal of this webinar is to help healthcare professionals improve care coordination for patients with advanced illness and to reduce hospital readmissions and length of stay (LOS).
The goal of this webinar is to educate healthcare professionals about the differences between palliative and curative care while exploring the history and philosophy of the hospice movement.
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar is to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis and the “death rattle” in patients with end-of-life respiratory symptoms.
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD) and the value of advance care planning (ACP) for end-of-life patients.
Presentation delivered by Dr Ellie Hitchman, Speciality Doctor and Kim Barlow, Specialist Physiotherapst from St Joseph's Hospice, Hackney, at the Pan London Airways Network Winter Meeting 2016
chronic obstructive pulmonary disease and its management
chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lungs.
COPD typically has a clear cause and a clear path of prevention, and there are ways to slow the progression of the disease.
Advanced Lung Disease: Prognostication and Role of HospiceVITAS Healthcare
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD), the value of advance care planning (ACP) and the benefits of hospice for end-of-life patients.
Risk of pulmonary aspiration with the outpatient electroconvulsive therapy: C...Ahmed Elaghoury
A case study presented at the 2nd International Brain Stimulation in Barcelona.
Cite as: Gad, M., & Elaghoury, A. (2017). Risk of pulmonary aspiration with the outpatient electroconvulsive therapy: Case report. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, 10(2), 419.
http://dx.doi.org/10.1016/j.brs.2017.01.244
APA format 2 pages 3 references 2 from walden university library. brockdebroah
APA format 2 pages 3 references 2 from walden university library.
As a registered nurse working as a case manager within the home health care setting, I have had the opportunity to provide care to patients diagnosed with various respiratory disorders. A majority of the patients I have worked with were diagnosed with chronic obstructive pulmonary disease (COPD). COPD is defined as a common preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases (Huether, 2017). Two important facts regarding this respiratory disorder include the following:
COPD is the third leading cause of death in the United States accounting for 138,080 deaths in 2010.
In 2010, the cost of COPD in the United States was estimated to be nearly $50 billion, including nearly $30 billion in direct health care expenditures.
These figures detail the staggering numbers of patients living with COPD and the significant impact on patients, families, communities and the health care system.
During the time that I worked with COPD patients, one of the respiratory disorders of particular interest was emphysema. I wanted to make sure I understood the disease process so I could provide the most appropriate care and teaching to my patients, families and caregivers. Emphysema is abnormal permanent enlargement of gas-exchange airways (acini) accompanied by destruction of alveolar walls without obvious fibrosis (Huether, 2017). Furthermore, the American Lung Association defined emphysema as the gradual damage of lung tissue, specifically thinning and destruction of the alveoli or air sacs (
www.lung.org
). I often used this definition with patients to help them understand how this respiratory disorder effects the body. The pathophysiology of emphysema includes the following:
Air sacs are destroyed in emphysema, making it progressively difficult to breathe.
Emphysema is usually accompanied by chronic bronchitis, with almost-daily or daily cough and phlegm.
Cigarette smoking is the major cause of emphysema.
People with emphysema experience shortness of breath with activities
It is not curable, but there are treatments that can help you manage the disease (www.lung.org).
Medication management of emphysema varies depending upon severity of the disease. Initial drug therapy selection depends on COPD severity, symptoms, and exacerbation risk. In addition, medication therapy may be based upon Global Obstructive Lung Disease (GOLD) guidelines which categorized COPD into four groups (A, B, C, D) ranging from low risk, less symptoms to high risk, high symptoms (Arcangelo, 2017). Medications may include the following:
Short-acting beta2 agonists, short-acting anticholinergics, combination of short-acting anticholinergic and short-acting beta2-adrenergic agonists, long-acting beta2-agonists, l ...
Advanced Lung Disease: Prognostication and Role of HospiceVITASAuthor
The goal of this webinar was to educate physicians and healthcare professionals about the medical management of advanced lung disease (ALD), the value of advance care planning (ACP) and the benefits of hospice for end-of-life patients.
Running head RESPIRATORY CLINICAL CASE .docxtodd521
Running head: RESPIRATORY CLINICAL CASE 1
RESPIRATORY CLINICAL CASE 2
Respiratory Clinical Case
Ram Pandey
South University Online
Dr. Judith Cornelius
NSG 6001
Date: 04/08/2019
Patient Initials: CF Gender: Female Age: 65
Subjective Data
Chief Complaint
Patient comes to the clinic with the chief complaints of shortness of breath, wheezing and mild coughing.
HPI
For the last 2 months, patient has experienced asthma attacks on average more than 4 times a week, posttraumatic seizure 2 weeks after the accident and serious MVA 10 weeks ago. Anticonvulsant phenytoin started recently and there has not been any seizure activity since the initiation of therapy.
PMH
Patient has a history of periodic asthma attacks dating back to her early 20s. Three years ago, patient was diagnosed with mild congestive heart failure and placed on hydrochlorothiazide and sodium restrictive diet. Last year, CF placed on enalapril because of worsening CHF. Medication has controlled the symptoms relatively well the last year. Apart from enalapril, other medications prescribed for the patient include albuterol inhaler, theophylline SR capsules 300 mg PO BID, and PRN Phenytoin SR capsules 300 mg PO QHS. She has no known allergies. Patient has not had any surgeries.
Family History
The patient’s parents are both deceased. Her father succumbed to kidney failure at age 59 while her mother died of CHF aged 62
Social History
Patient attests that she is a nonsmoker and she does not consume alcohol. She takes four cups of diet colas and the same number of coffee cups
ROS
Positive for cough, wheezing, exercise intolerance and shortness of breath. Denies seizures, headaches and swelling of extremities
Gen
Pale, well-developed Caucasian female appearing to be anxious. HEENT: PERRLA, oral cavity without lesions, TM without signs of inflammation, no nystagmus noted. Abdomen: non-tender, soft, non-distended no masses. Chest: Bilateral expiratory wheezes. Cardio: Regular rate and rhythm normal S1 and S2. Rectal: Guaiac negative. GU: Unremarkable. NEURO: A&O X3, cranial nerves intact. EXT: +1 ankle edema, on right, no bruising, normal pulses.
Objective Data
Vital Signs: BP 171/94, HR 122, RR 31, T 96.7 F, Wt 145, Ht 5’ 3”. After the albuterol treatment, vital signs are BP 134/79, HR 80, and RR 18
Physical Assessment and Diagnostic Testing: Na – 134, K - 4.9, Cl – 100 (all within normal limits), BUN – 21, Cr - 1.2, Glu – 110, Theophylline - 6.2, Phenytoin – 17, ALT – 24, AST – 27, Total Chol – 190 (substantially high, predicted moderate restriction). CBC – WNL, Chest Xray – Blunting of the left and right costophrenic angles, Peak Flow – 75/min (relatively low, normal should be between 80-100/min); after albuterol – 102/min, FEV1 – 1.8 L; FVC 3.0 L, FEV1/FVC 60% (predicted moderate obstruc.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
When Decision-Making Is Imperative: Advance Care Planning for Busy Practice S...VITAS Healthcare
Complex, chronically ill patients present an opportunity to discuss and implement hospice and palliative care. Many elderly patients who present to the ED and other busy practice settings are hospice-eligible because of functional decline and multi-morbidity. Key tools can quickly facilitate goals-of-care (GOC) conversations, advance care planning, and hospice referrals amid time constraints and high-acuity challenges.
Assessment and Management of Disruptive Behaviors in Persons With DementiaVITAS Healthcare
This webinar helps physicians conduct a systematic evaluation for behavioral changes
in persons with dementia. It offers approaches for developing a comprehensive care plan for
disruptive behaviors. These methods incorporate caregiver education and non-pharmacologic
interventions followed by pharmacologic management.
Pain Management in the Context of an Opioid Epidemic: Considerations and Tool...VITAS Healthcare
This presentation details how to conduct a comprehensive pain assessment, considerations when prescribing analgesics, and when opioids may be appropriate.
Understanding Pain Management and Daily Practice ManagementVITAS Healthcare
Supported by evidence-based data, this webinar helped physicians and healthcare professionals gain greater understanding of the multifaceted applications of pain management in the context of palliative hospice care.
The goal of this webinar was to educate healthcare professionals about advance directives and advance care planning,
including the types and purposes of legal documents that govern patients’ decisions and
preferences.
The goal of this webinar was to help healthcare professionals improve care coordination for patients with advanced illness and to reduce hospital readmissions and length of stay (LOS).
The goal of this webinar was to educate physicians and healthcare professionals about hospice eligibility and the benefits of hospice for patients with advanced cardiac disease (ACD).
The goal of this webinar was to educate healthcare professionals about the differences between palliative and curative care while exploring the history and philosophy of the hospice movement.
The goal of this webinar was to equip healthcare professionals with an understanding of military veterans’ unique medical, emotional, and spiritual needs as they near the end of life.
The goal of this webinar was to equip healthcare professionals with an understanding of military veterans’ unique medical, emotional, and spiritual needs as they near the end of life.
The clinical case study of a patient with advanced COPD who has multiple comorbid conditions and develops sepsis provideD the backdrop for two potential clinical pathways—sepsis and post-sepsis syndrome.
Understanding Pain Management and Daily Practice ManagementVITAS Healthcare
Supported by evidence-based data, this webinar helped physicians and healthcare professionals gain greater understanding of the multifaceted applications of pain management in the context of palliative hospice care.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
Key tools can quickly facilitate goals-of-care (GOC) conversations, advance care planning, and hospice referrals amid the ED’s time constraints and high-acuity challenges.
Assessment and Management of Disruptive Behaviors in Persons with DementiaVITAS Healthcare
This webinar helps physicians conduct a systematic evaluation for behavioral changes in persons with dementia. It offers approaches for developing a comprehensive care plan for disruptive behaviors.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
2. CE Provider
Information
VITAS Healthcare programs are provided CE credits for their Nurses/Social
Workers and Nursing Home Administrators through: VITAS Healthcare
Corporation of Florida, Inc./CE Broker Number: 50-2135. Approved
By: Florida Board of Nursing/Florida Board of Nursing Home
Administrators/Florida Board of Clinical Social Workers, Marriage and Family
Therapy & Mental Health Counseling.
VITAS Healthcare programs in Illinois are provided CE credit for their Nursing
Home Administrators and Respiratory Therapists through: VITAS Healthcare
Corporation of Illinois, Inc./8525 West 183 Street, Tinley Park, IL 60487/NHA
CE Provider Number: 139000207/RT CE Provider Number: 195000028/Approved
By the Illinois Division of Profession Regulation for: Licensed Nursing Home
Administrators and Illinois Respiratory Care Practitioner.
VITAS Healthcare, #1222, is approved to offer social work continuing education
by the Association of Social Work Boards (ASWB) Approved Continuing
Education (ACE) program. Organizations, not individual courses, are approved
as ACE providers. State and provincial regulatory boards have the final authority
to determine whether an individual course may be accepted for continuing
education credit. VITAS Healthcare maintains responsibility for this course.
ACE provider approval period: 06/06/2018 – 06/06/2021. Social workers
completing this course receive 1.0 ethics continuing education credits.
VITAS Healthcare Corporation of California, 310 Commerce, Suite 200, Irvine,
CA 92602. Provider approved by the California Board of Registered Nursing,
Provider Number 10517, expiring 01/31/2021.
Exceptions to the above are as follows: AL: No NHAs, DE: No NHAs, DC: No
NHAs, GA: No NHAs, KS: No NHAs,NJ: No NHAs, OH: No NHAs, PA: No NHAs,
TX: No NHAs, VA: No NHAs, WI: No NHAs and Nurses are not required – RT
only receive CE Credit in Illinois.
3. Goal
The goal of this presentation is to educate
healthcare professionals on effective and
competent management of respiratory
symptoms so that terminally ill patients and
their families may receive optimal hospice
and palliative care.
4. Therapeutic
Goal
Development of respiratory symptoms
such as dyspnea, cough, hiccups, and
secretions is common at end of life and
can often be anticipated.
The optimal therapeutic goal when
confronted with a patient experiencing
respiratory symptoms is to treat the
underlying condition (if possible).
5. Objectives
• Define dyspnea, cough, and hemoptysis
• List palliative treatment options
• Describe pharmacologic and
non-pharmacologic interventions
• Explain the “death rattle” and effective
treatment agents
6. Case of LM
• LM is a 68-year-old male with history of metastatic
non-small cell lung cancer (NSCLC) and chronic
obstructive pulmonary disease (COPD), admitted
to the medical floor with shortness of breath
(SOB), wheeze, and bloody cough (hemoptysis)
• A large inoperable mass in the mediastinum
involves the right main stem bronchus with
post-obstructive pneumonia
• LM has undergone radiation treatment for the
mass and laser ablation to control hemoptysis
• Fever, severe dyspnea, and cough add to his
overall symptom burden
• LM has lost 18% of his body weight in the last
three months, is weak and fatigued, and requires
assistance in 3/6 activities of daily living (ADLs)
7. Dyspnea
• Subjective feeling of SOB
• A common respiratory symptom at the
end of life (EOL)
– Only 11.4% of patients at EOL report
no dyspnea
– Often related to other advanced illnesses:
• Advanced heart failure
• Advanced COPD and pulmonary fibrosis
• Pneumonia, aspiration, and sepsis
• Malignancy
• Pulmonary embolism
– Medical treatments: Chemotherapy, XRT,
other medications
Kamal, A., Maguire, J., Wheeler, J., Currow, D.,& Abernethy, A. (2011). Dyspnea review for the palliative
care professional: assessment, burdens, and etiologies. Journal of Palliative Medicine, 14(10):1167–1172.
8. Dyspnea
(cont.)
• Unmanaged dyspnea and other respiratory
symptoms are key drivers of emergency
department (ED) utilization and
hospitalization in patients with life-limiting
and advanced illness
• Evidence shows that 50% of solid tumor
cancer patients with dyspnea who present
to the ED die within six months
Koelwyn, G., Jones, L., Hornsby, W., & Eves, N. (2012). Exercise therapy in the management of dyspnea in patients
with cancer. Current Opinion in Supportive and Palliative Care, 6(2):129–137. doi:10.1097/SPC.0b013e32835391dc
9. Dyspnea
(cont.)
• Frequently associated with
other symptoms:
– Asthenia
– Anxiety
– Insomnia
– Pain
• Recognized to be more difficult
to evaluate and treat than pain
• Median length of stay for patients
experiencing dyspnea was longer
than those without the symptom
Guirimand, F., Sahut d'izarn, M., Laporte, L., Francillard, M., Richard J.,& Aegerter P. (2015). Sequential occurrence of dyspnea
at the end of life in palliative care, according to the underlying cancer. Cancer Medicine, 4(4):532–539. dx.doi:10.1002/cam4.419
10. Types of
Dyspnea
Continuous Dyspnea: Dyspnea that
is always present
– Reported by 39% of patients
Breakthrough Dyspnea: Short periods
of dyspnea interspersed with periods of
no breathlessness throughout the day
– Reported by 80% of patients with SOB
– 5-6 episodes per day lasting 5 minutes
or less
Reddy, S., Parsons, H., Elsayem, A., Palmer, J., & Bruera, E. (2009). Characteristics and correlates
of dyspnea in patients with advanced cancer. Journal of Palliative Medicine, 12(1):29-36.
11. Assessment
of Dyspnea
Dyspnea is highly subjective and often
based on patient-reported severity,
similar to pain.
Kamal A., Maguire J., Wheeler J., Currow D., & Abernethy A. (2011). Dyspnea review for the palliative
care professional: assessment, burdens, and etiologies. Journal of Palliative Medicine, 14(10):1167–1172.
Patient Descriptors of Dyspnea
I feel… My… I cannot…
That I am smothering Breathing requires effort Take a full breath
That my breath stops Chest feels tight Get enough air
That I am suffocating Breathing is fast
Stop thinking about
my breathing
12. Assessment
of Dyspnea
(cont.)
Conduct a careful history and
physical examination.
• Note the presence or
absence of:
– Wheeze
– Crackles
– Lung sounds
– Peripheral edema
– Cyanosis
• Note patient’s use of
accessory muscles
13. Dyspnea
Management
Kamal A., Maguire J., Wheeler J., Currow D., & Abernethy, A. (2011). Dyspnea review for the palliative
care professional: assessment, burdens, and etiologies. Journal of Palliative Medicine, 14(10):1167–1172.
Biopsychosocial Model of Dyspnea Management
14. Treatments
for Dyspnea
Understand underlying cause
to optimize treatment:
• Hypoxemia: Oxygen therapy
• Asthma/COPD: Bronchodilators, oral
steroids, occasional antibiotics, and
occasional surgical interventions
• Pneumonia and URI: Antibiotics,
bronchodilators, steroids (sometimes)
• Heart failure and edema: Diuretics,
optimal medical management, and
inotropes (sometimes)
• Pleural effusions: Thoracentesis
• Solid tumors: XRT, surgical interventions
15. • Opioids are highly effective in managing the
symptoms of SOB in advanced illness patients
– Intermittent and/or continuous dosing can be
used depending on underlying cause, other
symptoms, and type of dyspnea
• Opioids’ effects are due to ventilatory response
to carbon dioxide, hypoxia, inspiratory flow-
resistive loading, vasodilatory effect on pulmonary
vascular pressures, and decreased oxygen
consumption with exercise
• Multiple studies have shown that opioids are
safe in this population
• When anxiety is present with dyspnea,
benzodiazepines or SSRI can be added as
adjuvant therapy
Opioids for
Patients With
Dyspnea
Nearing End
of Life
16. Case of LM
(cont.)
LM received 5 mg of IV morphine
in ED along with nebulizers, oxygen,
Tylenol, and first-dose antibiotics.
• Three days later:
– Fever and chills have subsided
– LM is weaker, has SOB at rest, and
requires continuous oxygen and
frequent doses of opioids
– He continues to have persistent
cough and occasional hemoptysis
After LM's goals-of-care (GOC) conversation
with the hospitalist, a hospice consultation
is recommended.
17. Cough
• A normal physiologic function designed
to protect the airways by removing
mucus and foreign materials
• Cough is under both involuntary and
voluntary control
• Cough reflex is mediated by the
vagus nerve in the airways and the
glossopharyngeal nerve in the pharynx
• Cough is stimulated by mechanical
or chemical irritation of the trachea
or bronchi, or by pressure from
adjacent structures
18. Cough
(cont.)
• Cough occurs in 30%-50% of all
patients at the end of life
• Approximately 80% of lung cancer
patients and patients whose death
is imminent will have cough as a
major symptom
• Ineffective cough is common in
advanced illness such as COPD and
cancer, leading to pooling of
secretions and even dyspnea
• Refractory cough can also be present
– Requires aggressive management
to prevent complications
19. Causes of
Cough in
Advanced
Illness
Non-Cancer Related:
• End-stage (ES)
cardiac disease
• ES pulmonary disease
• ES renal disease
• Neuromuscular
(MS, ALS)
• Late-stage dementias
• GERD
• Cerebrovascular disease
• Medications (ACEi)
Bonneau, A. (2009). Cough in the palliative care setting. Canadian Family Physician. 55(6):600–602.
Cancer Related:
• Pulmonary mass
or involvement
• Intrinsic/extrinsic
airway obstruction
• SVC syndrome
• Aspiration
• PE
• Chemotherapy-
induced
20. Symptoms
Caused by
Cough
• Loss of appetite
• Headache
• Dizziness
• Sleep disturbance
• Fatigue
• Infections/pneumonia
Bonneau, A. (2009). Cough in the palliative care setting. Canadian Family Physician. 55(6):600–602.
21. Evaluation
of Cough
Thorough history and physical exam
help define cause and most appropriate
plan of care.
• Understanding underlying etiology
determines appropriate intervention:
– Non-pharmacologic
– Pharmacologic
• Determination of severity of cough:
mild, moderate, or severe
22. Non-
Pharmacologic
Treatment
• Proper positioning of patient to
promote drainage of secretions and
minimize gastric reflux or aspiration
• Chest physical therapy/percussion
therapy to help mobilize
difficult secretions
• Air humidifiers
• Saline nebulizers to minimize
airway irritation and dryness
• Minimize exposure to perfumes and
aromas that can trigger cough
• Lozenges and hard candies
23. Pharmacologic
Treatment
Many medications can be used to
help manage cough in patients with
life-limiting and advanced illness.
• Main categories:
– Peripherally acting agents
– Centrally acting agents
– Other and mixed agents
Medications are utilized to suppress
cough directly, mobilize secretions,
or treat secondary causes of cough.
24. Mild Cough
• Non-pharmacologic interventions
are preferred
• Benzonatate is a stretch receptor
anesthetic agent
• Nebulizers in those with COPD
or asthma
• Dextromethorphan
• Guaifenesin to help thin secretions
25. Moderate
to Severe
Cough
• Opioids are first-line therapy
– Morphine 5 mg q4H
• Gabapentin and pregabalin can be
tried in those who cannot tolerate
opioid therapy; more frequently
used in chronic cough situations
• Nebulized anesthetic agents
(e.g. lidocaine, bupivacaine)
can offer some relief
Yancy Jr, W. S., McCrory, D. C., Coeytaux, R. R., Schmit, K. M., Kemper, A. R., Goode, A., ... &
Sanders, G. D. (2013). Efficacy and tolerability of treatments for chronic cough. Chest, 144(6):1827-1838.
26. Severe
Refractory
Cough
• May require a multifocal approach
combining non-pharmacologic and
pharmacologic approaches
• Opioids with inhaled anesthetics to
gain control of refractory cough with
addition of gabapentinoids to suppress
the neuroexcitatory component
29. Case of LM
(cont.)
• LM is started on low-dose methadone and
gabapentin for his cough, and morphine
(as needed) for breakthrough episodes
of cough and pain
• During his GOC conversation, he reports
a desire to return home and stay at home
• He and his family elect home hospice
as his disposition plan; five days following
his admission, he is discharged home
on hospice
• One week after discharge, he begins to
have significant worsening of cough and
hemoptysis; an on-call hospice nurse is
dispatched to his home
30. Hemoptysis
Hemoptysis is the expectoration of
blood, usually derived from the lungs
or bronchial tubes as a result of
pulmonary or bronchial hemorrhage.
• A number of sources exist:
– Tracheobronchial
– Non-lower respiratory
– Pulmonary parenchymal
– Primary vascular
31. Hemoptysis
(cont.)
Lung cancer patients present with
hemoptysis 30%-50% of the time.
• Common causes
– Pneumonia
– Lung cancer
– Acute/chronic bronchitis
– Pulmonary embolus
– Tuberculosis
Jacob, L., Bidwell, M., Pachner, M. (2005). Hemoptysis: Diagnosis and
Management. American Family Physician, 72(7): 1253-1260.
32. Evaluation
Careful history and physical are
important to distinguish hemoptysis
from hematemesis and upper
respiratory sites of bleeding.
• Hematemesis is the spitting up
or vomiting of blood; it is often
confused with hemoptysis
– Source is the esophagus,
stomach, and upper GI
Ruling out hematemesis allows for
accurate diagnosis of hemoptysis
etiology and drives the treatment plan.
33. Determining
Severity of
Bleeding
Non-massive Hemoptysis:
• Minimal blood production
• Normal vital signs
• No abnormal gas exchange
Massive Hemoptysis:
• Hemodynamic instability and
abnormal gas exchange present
• Tachycardia
• Hypotension
• Tachypnea
• Hypoxemia
34. Hemoptysis
Evaluation
American College of Radiology
Appropriateness Criteria for Imaging
in Patients With Hemoptysis:
• Initial evaluation of patients with hemoptysis
should include chest radiography
• In patients at high risk of malignancy with
normal findings on chest radiography,
CT, and bronchoscopy:
– Observation for three years may
be considered
– Radiography and CT should be performed at
follow-up based on the patient’s risk factors
– Bronchoscopy may be performed in addition
to imaging during the observation period
Earwood, J., Thompson, T. (2015). Hemoptysis: Diagnosis and Management. American Family Physician, 15;91(4):243-249.
35. Hemoptysis
Evaluation
(cont.)
• CT should be considered:
– For initial evaluation in patients at high risk
of malignancy or suspicious findings on
chest radiography
– In current/former smokers with normal
findings on chest radiography
• Massive hemoptysis can be treated with:
– Surgery or percutaneous embolization
– Multidetector CT before embolization or
surgery can define the source of hemoptysis
– Percutaneous embolization may be
used initially to halt hemorrhage before
definitive surgery
Earwood, J., Thompson, T. (2015). Hemoptysis: Diagnosis and Management. American Family Physician, 15;91(4):243-249.
38. Etiology
Tracheobronchial sources:
• Bronchitis, trauma, or foreign bod
Parenchymal sources:
• Infections (abscess, PNA, TB),
vasculitis, and trauma
Primary vascular sources:
• AVM, PE, elevated PAP, pulmonary
artery rupture from procedure
Other causes to consider:
• Medications, particularly anticoagulation
39. Treatment for
Hemoptysis
• Cough suppressants
• Saline nebulizers for airway irritation
• Visualization and therapy
via bronchoscopy
• Interventional radiology for large bleeding
• CT-guided embolization
• Bronchial arteriogram with embolization
• Supportive care
• Psychosocial support
• Patient and family education about
possibilities of massive hemoptysis
41. Massive
Hemoptysis
• Massive hemoptysis is a rare condition
occurring in about 1%-4% of all patients
• Death may occur very suddenly
• Patients will cough up massive
amounts of blood
• Rapid and physically
painless exsanguination
• Exceedingly traumatic for the family
− Recommendation: have dark-colored
towels available
42. Mortality
Prediction in
Hemoptysis
Earwood, J., Thompson, T. (2015). Hemoptysis: Diagnosis and Management. American Family Physician, 15;91(4):243-249.
Predictors of In-Hospital Mortality in Patients with Hemoptysis
Chest radiography on admission shows
involvement of two or more quadrants (1 point)
Chronic alcoholism (1 point)
Pulmonary artery involvement (1 point)
Aspergillosis (2 points)
Malignancy (2 points)
Mechanical ventilation
required (2 points)
Score 0 1 2 3 4 5 6 7
Mortality 1% 2% 6% 16% 34% 58% 79% 91%
NOTE: Patients with a score greater than 2 should be admitted to the intensive care unit, and
those with a score greater than 5 may require urgent interventional radiology.
Adapted with permission from Fartoukh M, Khoshnood B, Parrot A, et al. Early pre-diction of
in-hospital mortality of patients with hemoptysis: an approach to defining severe hemoptysis.
Respiration. 2012;83(2):111.
43. Case of LM
(cont.)
• At time of hospice nurse’s visit, LM is found to
have SOB, cough, and moderate hemoptysis
• Hospice nurse contacts hospice physician,
who orders continuous home care to evaluate
and manage symptoms
• LM is now confused, cyanotic, and
minimally responsive
• Oral medications are discontinued; LM is
started on liquid SL methadone and liquid
SL morphine, with doses titrated to manage
cough and shortness of breath
• As his cough improves, his bleeding stops
• 24 hours later, he becomes unresponsive
and develops noisy airway secretions
44. Respiratory
Secretions
• Noisy, moist breathing presents within
several days of death in 60%-90%
of patients
• Caused by air passing through airways
with secretions present (as the patient
is unable to swallow or clear them)
• Two types:
– Excessive oral secretions
– Excessive bronchial secretions
• Secretions can be thin or thick
in consistency
45. Respiratory
Secretions
(cont.)
• There is limited evidence to support
secretions as a source of discomfort
to patients near the end of life
• Secretions are often associated
with the active dying process and a
prognosis of hours to days
• There is conflicting evidence regarding
effectiveness of pharmacologic therapy
• Simple measures of repositioning
seem to be most effective
46. Management
of Respiratory
Secretions
• Repositioning patient to promote secretion
drainage and prevent pooling of secretions
• Educate family that secretions are
normal at end of life
• For thick secretions, saline nebulizers
help to thin and mobilize them
• Anticholinergic medications:
– Atropine
– Hyoscyamine
– Glycopyrrolate
– Scopolamine
47. Similar
Medication
Effectiveness
Wildiers, H., Dhaenekint, C., Demeulenaere, P., Clement, P. M., Desmet, M., Van Nuffelen, R., ... & Menten, J. (2009).
Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care.
Journal of Pain and Symptom Management, 38(1); 124 – 133.
33
42
50
71
76
95
80 80
27
42
54 52
60
56
62
50
28
37
47
57
68
56
100
67
0.0
16.7
33.4
50.1
66.8
83.5
100.2
0.5 1 4 12 24 72 96 120
PercentageEffective
Hours
Atropine Hyoscine butylbromide Scopolamine
94 94
90
84 83
88
83
75 75
24
38
51
61
68
87
69
79
67
7
17
25
40
57 58
64
75
67
0.0
16.7
33.4
50.1
66.8
83.5
100.2
0.5 1 4 12 24 48 72 96 120
PercentageEffective
Hours
Baseline Rattle Score 1 Baseline Rattle Score 2 Baseline Rattle Score 3
48. Conflicting
Evidence of
Anticholinergics
• 2013 study by Heisler, et al., looked at
atropine administration vs. placebo in
177 patients with terminal secretions
• Results showed no difference in severity
of terminal secretions between atropine and
placebo groups
• Noise scores improved in both groups,
suggesting a favorable natural course
for this symptom
Heisler, M., Hamilton, G., Abbott, A., Chengalaram, A., Koceja, T., & Gerkin, R. (2013) Randomized double-blind trial of
sublingual atropine vs. placebo in the management of death rattle. Journal of Pain and Symptom Management, 45(1): 14-22.
49. Cautions
Suctioning has been noted to be
ineffective and should be avoided
in the dying patient, in most cases.
Always be prudent when using
anticholinergic medications to avoid
over-utilization and many adverse effects:
– Delirium
– Confusion
– Agitation
– Hyperthermia
– Urinary retention
– Tachycardia
– Dry mouth
51. Hospice
Eligibility
Guidelines
for Patients
with Advanced
Lung Disease
(ALD)
• Dyspnea at rest or with minimal exertion
• Dyspnea which is unresponsive or poorly
responsive to bronchodilator therapy
• Progression of chronic pulmonary
disease as evidenced by one or more
of the following:
– Frequent use of medical services,
including hospitalizations, ED visits,
and/or physician outpatient visits
due to symptoms of pulmonary disease
52. Hospice
Eligibility
Guidelines
for Patients
with ALD
(cont.)
• Frequent episodes of bronchitis
or pneumonia
• Unintentional weight loss of ≥ 10% body
weight over the preceding six months
• Progressive inability to independently
perform various ADLs or an increasing
dependency with ADLs, resulting in a
progressively lower performance status
54. Abnormal
Lab Findings
While these laboratory studies may be
helpful to the clinician when considering
patient eligibility for hospice, they are not
required for patient admission:
• FEV1 ≤ 30% predicted post-bronchodilator
• Serial decreases in FEV1 of at least
40 mL/year over several years
• PO2 ≤ 55 mmHg on room air
• O2 sat. ≤ 88% on room air
• Persistent hypercarbia (pCO2)
≥ 50 mmHg
55. Conclusions
• Breathing is a gift. Although each breath
comes naturally to most of us, breathing
is a struggle for some patients.
• Offer assistance to patients and families
to help them cope with the respiratory
challenges they may face at the end of life.
57. References
Bonneau, A. (2009). Cough in the palliative care setting. Canadian Family
Physician. 55(6):600–602.
Earwood, J., Thompson, T. (2015). Hemoptysis: Diagnosis and Management.
American Family Physician, 15;91(4):243-249.
Guirimand, F., Sahut d'izarn, M., Laporte, L., Francillard, M., Richard J.,
& Aegerter P. (2015). Sequential occurrence of dyspnea at the end of life
in palliative care, according to the underlying cancer. Cancer Medicine,
4(4):532–539. dx.doi:10.1002/cam4.419
Heisler, M., Hamilton, G., Abbott, A., Chengalaram, A., Koceja, T., & Gerkin,
R. (2013) Randomized double-blind trial of sublingual atropine vs. placebo
in the management of death rattle. Journal of Pain and Symptom Management,
45(1): 14-22.
Jacob, L., Bidwell, M., & Pachner, M. (2005). Hemoptysis: Diagnosis and
Management. American Family Physician, 72(7): 1253-1260.
58. References
(cont.)
Kamal, A., Maguire, J., Wheeler, J., Currow, D., & Abernethy, A. (2011).
Dyspnea review for the palliative care professional: assessment,
burdens, and etiologies. Journal of Palliative Medicine, 14(10):1167–1172.
Koelwyn, G., Jones, L., Hornsby, W., & Eves, N. (2012). Exercise therapy in the
management of dyspnea in patients with cancer. Current Opinion in Supportive
and Palliative Care, 6(2):129–137. doi:10.1097/SPC.0b013e32835391dc
Reddy, S., Parsons, H., Elsayem, A., Palmer, J., & Bruera, E. (2009).
Characteristics and correlates of dyspnea in patients with advanced cancer.
Journal of Palliative Medicine, 12(1):29-36.
Wildiers, et al. (2009). Atropine, hyoscine butylbromide, or scopolamine
are equally effective for the treatment of death rattle in terminal care.
Journal of Pain and Symptom Management, 38(1); 124 – 133.
Yancy Jr, W. S., McCrory, D. C., Coeytaux, R. R., Schmit, K. M., Kemper, A. R.,
Goode, A., ... & Sanders, G. D. (2013). Efficacy and tolerability of treatments for
chronic cough. (2013). Chest, 144(6):1827-1838.